

ASAIO TRANSACTIONS-VOLUME 33

Subject Index

Editors' Note: This index encompasses only the material presented in ASAIO TRANSACTIONS Volume 33, Numbers 1, 2, and 4. Please consult the July-September issue (Vol. 33, No. 3) for an index of the contents of that body of work.

A

Admissions and Policy Committee, Northwest Kidney Center, 791
Adsorption, protein
 preadsorption and, 78
 surface properties and, 75
Age, CAPD and, morbidity and mortality with, 57
Antithrombotic therapy
 biocompatibility and, 824
 pharmaceutically active surfaces and, 82
ASAIO, the Committee and (Moment in History), 791
Atherosclerosis, extracorporeal lipid extraction and, 813

B

Biocompatibility, 824
Biomaterials
 cell adhesion to, 66
 encapsulated endocrine cells, modified versus, 787
 infection, neoplasia, and calcification associated with, 8
Bionic heart substitutes, biologic versus, 51
Bionic insulin, natural versus, 806
Biosensors, 834
 enzymatic, implanted, long-term stability of, 837
 sterilization of, 840
Blood compatibility, surfaces and, 75
Blood substitutes, based on modified hemoglobin and fluorochemicals, 819

C

Calcification, biomaterial-associated, 8
CAPD. *See* Continuous ambulatory peritoneal dialysis
Capsules, polymeric, 806
Cardiogenic shock, temporary ventricular support for, 4
Catheters, peritoneal dialysis, use and complications of, 33
Cell adhesion, to biomaterials, 66
Chemical biosensors, 834
Cholesterol, extracorporeal lipid extraction and, 813
Continuous ambulatory peritoneal dialysis (CAPD), morbidity and mortality with, factors in, 57
Continuous drug infusion pumps, implantation of, rabbit model for, 28

D

Diabetic glomerulosclerosis, CAPD and, morbidity and mortality with, 57
Dialysis. *See also* Hemodialysis; Peritoneal dialysis with-drawal of, 794
Drug infusion pumps, continuous, implantation of, rabbit model for, 28
Dynamic surfaces, hydrated, 76

E

Endocrine cells, encapsulated versus modified, organ replacement and, 787

Enzymatic biosensors, implanted, long-term stability of, 837
Ethylene oxide, biosensor sterilization and, 840
Extracellular matrix, components of, and attachment of non-transformed fibroblasts and parenchymal cells, 66
Extracorporeal lipid extraction, 813

F

Fibroblasts, non-transformed, attachment of, role of extra-cellular matrix components in, 66
Fluorochemicals, blood substitutes based on, 819

G

Glomerulosclerosis, diabetic, CAPD and, morbidity and mortality with, 57
Glucose, as osmotic agent, peritoneal dialysis kinetics with, 19
Glucose electrode, enzyme-based, 837
Glycerol, as osmotic agent, peritoneal dialysis kinetics with, 19

H

Heart, transplantation of, biologic versus bionic substitutes in, 51
Hemodialysis. *See also* Dialysis
 home, failure of, 1
Hemofiltration, early days of, 54
Hemoglobin, modified, blood substitutes based on, 819
Hydrated dynamic surfaces, 76

I

Infection
 biomaterial-associated, 8
 prevention of, biosensor sterilization and, 840
Insulin, bionic versus natural, 806
Islet microencapsulation, 806
Islet transplantation, encapsulated versus modified endocrine cells for, 787

L

Left ventricular assist device, introduction of, 39
Lipid extraction, extracorporeal, 813

M

Microencapsulation
 hemoglobin, 819
 islet, 806
Microstructures, morphology and, surface, 80
Morbidity and mortality, factors associated with, among patients on CAPD, 57
Morphology, microstructures and, surface, 80

ASAIO TRANSACTIONS-VOLUME 33

Subject Index

Editors' Note: This index encompasses only the material presented in ASAIO TRANSACTIONS Volume 33, Numbers 1, 2, and 4. Please consult the July-September issue (Vol. 33, No. 3) for an index of the contents of that body of work.

A

Admissions and Policy Committee, Northwest Kidney Center, 791
Adsorption, protein
 preadsorption and, 78
 surface properties and, 75
Age, CAPD and, morbidity and mortality with, 57
Antithrombotic therapy
 biocompatibility and, 824
 pharmaceutically active surfaces and, 82
ASAIO, the Committee and (Moment in History), 791
Atherosclerosis, extracorporeal lipid extraction and, 813

B

Biocompatibility, 824
Biomaterials
 cell adhesion to, 66
 encapsulated endocrine cells, modified versus, 787
 infection, neoplasia, and calcification associated with, 8
Bionic heart substitutes, biologic versus, 51
Bionic insulin, natural versus, 806
Biosensors, 834
 enzymatic, implanted, long-term stability of, 837
 sterilization of, 840
Blood compatibility, surfaces and, 75
Blood substitutes, based on modified hemoglobin and fluorochemicals, 819

C

Calcification, biomaterial-associated, 8
CAPD. *See* Continuous ambulatory peritoneal dialysis
Capsules, polymeric, 806
Cardiogenic shock, temporary ventricular support for, 4
Catheters, peritoneal dialysis, use and complications of, 33
Cell adhesion, to biomaterials, 66
Chemical biosensors, 834
Cholesterol, extracorporeal lipid extraction and, 813
Continuous ambulatory peritoneal dialysis (CAPD), morbidity and mortality with, factors in, 57
Continuous drug infusion pumps, implantation of, rabbit model for, 28

D

Diabetic glomerulosclerosis, CAPD and, morbidity and mortality with, 57
Dialysis. *See also* Hemodialysis; Peritoneal dialysis with-drawal of, 794
Drug infusion pumps, continuous, implantation of, rabbit model for, 28
Dynamic surfaces, hydrated, 76

E

Endocrine cells, encapsulated versus modified, organ replacement and, 787

Enzymatic biosensors, implanted, long-term stability of, 837
Ethylene oxide, biosensor sterilization and, 840
Extracellular matrix, components of, and attachment of non-transformed fibroblasts and parenchymal cells, 66
Extracorporeal lipid extraction, 813

F

Fibroblasts, non-transformed, attachment of, role of extra-cellular matrix components in, 66
Fluorochemicals, blood substitutes based on, 819

G

Glomerulosclerosis, diabetic, CAPD and, morbidity and mortality with, 57
Glucose, as osmotic agent, peritoneal dialysis kinetics with, 19
Glucose electrode, enzyme-based, 837
Glycerol, as osmotic agent, peritoneal dialysis kinetics with, 19

H

Heart, transplantation of, biologic versus bionic substitutes in, 51
Hemodialysis. *See also* Dialysis
 home, failure of, 1
Hemofiltration, early days of, 54
Hemoglobin, modified, blood substitutes based on, 819
Hydrated dynamic surfaces, 76

I

Infection
 biomaterial-associated, 8
 prevention of, biosensor sterilization and, 840
Insulin, bionic versus natural, 806
Islet microencapsulation, 806
Islet transplantation, encapsulated versus modified endocrine cells for, 787

L

Left ventricular assist device, introduction of, 39
Lipid extraction, extracorporeal, 813

M

Microencapsulation
 hemoglobin, 819
 islet, 806
Microstructures, morphology and, surface, 80
Morbidity and mortality, factors associated with, among patients on CAPD, 57
Morphology, microstructures and, surface, 80

N

- Neoplasia, biomaterial-associated, 8
- Northwest Kidney Center, Admissions and Policy Committee for, 791

O

- Oreopoulos-Zellerman catheters, 33
- Osmotic agents, glycerol and glucose as, peritoneal dialysis kinetics and, 19

P

- Pancreas, transplantation of, 806
- Pancreatic islets, transplantation of, encapsulated versus modified endocrine cells for, 787
- Parenchymal cells, attachment of, role of extracellular matrix components in, 66
- Perfluorochemicals, blood substitutes based on, 819
- Peritoneal dialysis. *See also* Dialysis
 - ambulatory, continuous, morbidity and mortality with, factors in, 57
 - catheter designs for, use and complications of, 33
 - kinetics of, with glycerol and glucose as osmotic agents, 19
- Pharmaceutically active surfaces, 82
- Polymeric capsules, 806
- Protein adsorption
 - preadsorption and, 78
 - surface properties and, 75
- Pump. *See also* Ventricular assist device(s)
 - implantable
 - insulin, 806
 - rabbit model for, 28

R

- Race, CAPD and, morbidity and mortality with, 57

S

- Sensors. *See* Biosensors
- Shock, cardiogenic, temporary ventricular support for, 4
- Sterilization, biosensor, 840
- Surfaces
 - dynamic, hydrated, 76
 - morphology of, microstructures and, 80
 - pharmacuetically active, 82
 - properties of, blood compatibility and, 75

T

- Tenckhoff catheters, 33
- Therapy, withdrawal of, 794
- Thromboembolic events, biocompatibility and, 824
- Transplantation. *See specific organ*
- Tumors, biomaterial-associated, 8

V

- Ventricular assist device(s)
 - left, introduction of, 39
 - temporary support with, 4

W

- Withdrawal of therapy, 794

X

- Xenotransplantation, 51

Author Index

A

Anderson, James M., 33:824
Andrade, J. D., 33:75

B

Bailey, Leonard L., 33:51
Berström, Jonas, 33:19
BlueMLE, Lewis W., Jr., 33:54
Buchwald, Henry, 33:28, 806

C

Chang, T. M. S., 33:819
Chenoweth, Dennis E., 33:824
Clagett, Patrick G., 33:824
Clark, Leland C., 33:834
Cooper, S., 33:75
Cutler, Sidney J., 33:57

D

Darrah, John B., 33:791
Delano, Barbara G., 33:1
Dombrovskis, Skai, 33:28

E

Eberhart, Robert C., 33:824
Esper, Eduardo, 33:28

F

Farmer, M., 33:819
Flanigan, Michael J., 33:33

Freeman, Richard M., 33:33
Friedman, Eli A., 33:794

G

Geyer, R. P., 33:819
Guilbeau, Eric J., 33:834

H

Hill, J. Donald, 33:824
Hirschman, Gladys H., 33:57

J

Jauregui, Hugo O., 33:66

K

Kantrowitz, Adrian, 33:39
Kim, S. W., 33:75

L

Lindholm, Bengt, 33:19

M

Michalek, Van, 33:28
Moss, G., 33:819

N

Nagaoka, S., 33:75
Ngheim, Dai D., 33:33

Nolph, Karl D., 33:57
Novak, Joel W., 33:57

O

Okano, T., 33:75

P

Pae, Walter E., Jr., 33:4
Pizziconi, Vincent B., 33:834

R

Rohde, Thomas D., 33:28

S

Saal, Stuart D., 33:813
Schoen, Frederick J., 33:8, 824
Schulak, James A., 33:33
Schultz, Jerome S., 33:834
Steinberg, Seth M., 33:57
Sun, Anthony M., 33:787

U

Ullrich, Gary E., 33:33

W

Werynski, Andrzej, 33:19
Wigness, Bruce D., 33:28

